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ABSTRACT
The conference “Results and prospects of development of new polyphenolic 
drugs for cancer patients” took place at the N.N. Petrov National Medical Research 
Center of Oncology (PNMRCO) on May 31, 2017, and gathered researchers involved in 
development and evaluation of medicinal products based on the novel lignin-derived 
soluble polyphenolic polymer BP-Cx-1. BP-Cx-1 is the platform for a portfolio of 
innovative pharmacological products such as BP-C1, BP-C2 and BP-C3.
Natural substances, as safe and pluripotent 
candidates for designing medicinal products, draw interest 
of various scientific communities. At the present time 
methods for extraction and characterization of individual 
polyphenolic compositions and a solid evidence-based 
scientific database on potential molecular targets of these 
compositions have been developed.
Convincing nonclinical data, demonstrating, most of 
all, antioxidant properties of these compounds has been 
collected; some of these compositions (e.g., Genistein) are 
being evaluated in clinical trials.
At the same time, the data on pharmacological 
potential of derivatives of lignin, plant polyphenolic 
polymer are very scarce.
The conference “Results and prospects of 
development of new polyphenolic drugs for cancer 
patients” took place at the N.N. Petrov National Medical 
Research Center of Oncology (PNMRCO) on May 31, 
2017, and gathered researchers involved in development 
and evaluation of medicinal products based on the novel 
lignin-derived soluble polyphenolic polymer BP-Cx-1. 
BP-Cx-1 is the platform for a portfolio of innovative 
pharmacological products such as BP-C1, BP-C2 and BP-
C3.
BP-C1, a novel platinum-containing antineoplastic 
intramuscular drug developed for therapy of a number 
of cancer indications, is currently under evaluation in 
randomized clinical trials in patients with metastatic breast 
cancer. BP-C2, a novel radioprotector/radiomitigator, 
incorporating ammonium molybdate, is developed for 
supportive care of cancer patients treated with chemo/
radiotherapy. BP-C3, a novel pharmaceutical composition, 
comprising iron, selenium, A and C vitamins, is in animal 
studies as a geroprotector and a supportive care product 
for cancer patients.
Over 150 international scientists from research 
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centers of 6 countries have been taking active part in 
evaluation of potential of these products. To facilitate 
exchange of information and accelerate the translation 
from laboratory to clinical and commercial setting, 
a community of scientists with support from the 
pharmaceutical company Meabco AS (Copenhagen, 
Denmark) has arranged the scientific conference.
During the conference leading researchers 
presented results of their experimental work, inspiring 
panel discussions regarding the potential of this group of 
substances for the therapy and supportive care of cancer 
patients.
His complimentary address, Alexey M. Belyaev, 
Director of the N.N. Petrov National Medical Research 
Center of Oncology, devoted to the role of the PNMRCO 
in development of the new polyphenolic products and to 
the history of long-term productive collaboration between 
science and business.
Stig Loefberg, CEO of Meabco AS (Denmark), 
expressed his sincere gratitude to the management and 
scientific staff of the N.N. Petrov National Medical 
Research Center of Oncology for over a decade of 
productive collaboration, presenting data on the status of 
the project and sharing his vision on the role of products 
developed by the company in treatment and supportive 
care of cancer patients.
Stig Larsen (Norwegian University of Life Sciences, 
Oslo) presented data from two clinical trials of BP-C1 in 
metastatic breast cancer patients: «The effect of BP-C1 in 
treatment of Stage IV metastatic breast cancer (MBC)” and 
«The effect of BP-C1 on QoL and Toxicity in treatment of 
Stage IV metastatic breast cancer (MBC)”.
Two randomized, double-blind, placebo-controlled 
multicenter studies were performed with the similar semi-
crossover design. Study I was performed in 6 centers in 
Russia and Thailand (N=30 patients) and study II was 
performed in 4 centers in Thailand (N=31 patients). The 
demographic characteristics of MBC patients were nearly 
equal in two studies except for BMI (28.4 kg/m2 in Study 
I vs 22.5 kg/m2 in Study II) and duration of disease (from 
the date of diagnosis: 6.25 years in Study I vs 4.5 years in 
Study II).
Patients allocated to either BP-C1 or equal looking 
placebo by block randomization for 32 days treatment. At 
the end of this period, the placebo patient were switched to 
active BP-C1 for additional 32 days of treatment. Patients 
who completed 32 days of BP-C1 treatment were offered 
the opportunity to continue on BP-C1 for an additional 32 
days in an open-label extension protocol. After completion 
of the therapy with BP-C1 all patients were followed up 
for 28 days. The patients were given daily intramuscular 
injections of BP-C1 or placebo in the amount of 0.035 mg/
kg of body weight for 32 days. Biochemistry, hematology, 
National Cancer Institute Common Terminology Criteria 
for Adverse Events (CTC-NCI), European Organization 
for Research and Treatment of Cancer quality of life 
questionnaire (QOL-C30 and the breast cancer-specific 
BR23) were recorded at screening and after every 16 days 
of treatment. Computed tomography was performed at 
screening and every 32 days. Response Evaluation Criteria 
In Solid Tumors (RECIST) was used for classification. 
The status of Estrogen receptor (ER), Progesterone 
receptor (PR) and Human epidermal epidermal growth 
factor receptor (HER2) prior to the study were collected 
after finalization of the studies.
The sum of target lesions diameters increased by 
2.3% in Study I, and 8.9% in Study II in the BP-C1 group 
versus by 14.3% and 37.6% in the placebo groups after 
32 days of treatment, respectively. The difference between 
the groups was significant in favor of BP-C1 (P=0.04, P 
<0.001). Additionally, a significant difference in favor 
of BP-C1 detected regarding the RECIST classification 
(P=0.026, P<0.001). Effect of BP-C1 was superior on 
MBC patients with double or triple negative ER, PR and 
HER2 receptors. The effect of BP-C1 increased with 
increasing number of negative hormone receptors. 
No significant difference between BP-C1 groups and 
placebo groups was revealed regarding sum toxicity score 
(CTC-NCI) absolute change during 32 days of treatment 
in both studies (P=0.22). The increase in sum toxicity 
score was most pronounced in the placebo group. 
“Breast cancer related pain and discomfort” scores 
(QLQ-BR23) were significantly reduced (P=0.02) in the 
BP-C1 group (-8.9 absolute change), but increased slightly 
in the placebo group (+6.5) in Study I after 32 days of 
treatment. In Study II, Breast cancer related pain and 
discomfort last week” score was unchanged in the BP-C1, 
but increased non-significantly (p=0.12) in the placebo 
group. The Between-group differences were significant in 
favor of BP-C1 (P=0.03, P=0.05). 
In Study I, 26 AE related to the study drug was 
reported of which 20 recorded in the BP-C1 group and 
six in placebo. All the AE classified as mild to moderate. 
Among 20 AEs in BP-C1 group were nausea, blood lactate 
dehydrogenase increased and headache and among the six 
in Placebo group were proteinuria. In Study II, seven AE 
related to the study drug was reported. Of these, four in 
BP-C1 and three in Placebo. All the AE’s in the BP-C1 
group classified as mild to moderate but one AE in the 
Placebo group classified as severe. No Serious Adverse 
Events (SAE) related to the treatment drugs reported in 
neither of the two studies. 
In patients suffering from stage IV metastatic breast 
cancer, treatment with BP-C1 provided tumor growth 
arrest, was well tolerated, improved quality of life, and 
produced few and mild to moderate manageable AE’s. 
Antineoplastic effect of BP-C1 did not seem to depend on 
the hormonal status of the primary tumor. 
Irina A. Baldueva (N.N. Petrov Research Institute 
of Oncology, Saint-Petersburg) devoted her presentation 
to results of analyses of cytokines in blood plasma of 
metastatic breast cancer patients from clinical trials of 
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Information about levels of cytokines in cancer 
patients is an important component of evaluation of 
immune status, required for understanding of the antitumor 
immune response. Increased levels of pro-inflammatory 
cytokines, such as IL-6 and TNF-alpha, are associated 
with chronic inflammations and frequently observed 
in cancer patients. Such chronic inflammatory status is 
further complicated through the use of chemotherapeutic 
drugs.
Analyses of cytokines of patients with metastatic 
breast cancer who took part in a clinical trial of BP-
C1 was performed by the Scientific Department of 
Oncoimmunology of the PNMRCO. Sixty two samples 
of blood plasma collected from 25 female patients (at 
screening and after 32 days of interventions with BP-C1 
or Placebo) with confirmed metastatic breast cancer were 
analyzed. 27 selected cytokines were measured with the 
Luminex xMpa, a multiplex assay method. The set of 
analyzed cytokines comprised pro-inflammatory and anti-
inflammatory cytokines, as well as pleiotropic cytokines. 
ANCOVA test was applied to the results of the analyses 
(Meddoc, Norway).
It was shown that administration of BP-C1 did not 
affect levels of pro-inflammatory cytokines in cancer 
patients. Statistically significant changes in dynamics of 
IL-13 (p=0,028) and IL-7 (р=0,027) were noted in patients 
treated with BP-C1. IL13 – is a multifunctional interleukin 
responsible for pro- and anti-inflammatory reactions and 
regulation of haemopoiesis. IL-7 – lymphopoietic growth 
factor is mainly produced by non-hematopoietic cells: 
brain stromal cells, epithelial cells of the thymus and 
intestine, keratinocytes, liver cells, dendritic and follicular 
dendritic cells. Thus, detected induction of these cytokines 
in response to therapy with BP-C1 indicates positive effect 
of this agent on hematopoiesis.
Anastasia V. Malek (N.N. Petrov National 
Medical Research Center of Oncology, Saint-Petersburg; 
Oncosystema LTD, Moscow) delivered a talk on effect of 
BP-C1-based therapy on the profile of miRNA circulating 
in plasma of breast cancer patients. MicroRNAs 
(miRNAs), class of small regulatory RNAs, play essential 
role in cancer development and progression. Specific 
cancer-associated changes of the cellular miRNA profile 
have being demonstrated for various malignancies, 
including breast cancer. 
Alterations of cellular as well as extracellular 
profiles of miRNAs are supposed to reflect various clinical 
characteristics: metastatic potency, drug resistance, total 
or disease-free survival. Evaluation of these alterations 
might have diagnostic and predictive value. Patients with 
metastatic breast cancer were randomized into two groups. 
Patients of the first group (N=11) were treated with BP-C1, 
patients of the second group (N=12) received a placebo 
treatment, prior to the cross-over to therapy with BP-
C1. Each treatment course lasted 32 days, samples of the 
plasma were collected before onset of the therapy and after 
each treatment course. Thus, there were 2 samples from 
each patient of the first group, and 3 samples from each 
patient of the second group. Total RNA isolation and RT-
qPCR analysis of 179 plasma/serum associated miRNAs 
were performed using reagents from Exiqon, Denmark. 
Results were normalized using complex references value 
and expression level of each miRNA was averaged 
over five groups of samples. Statistical significance 
of the observed expression shifts was evaluated using 
nonparametric Mann-Whitney U test (GraphPad Prizm 
6.0). 
It was established that BP-C1 therapy induces 
increase of plasma concentration of hsa-let-7e-5p, hsa-
miR-532-5p, and decrease of plasma concentration of 
hsa-miR-26a-5p, hsa-miR-33a-5p, hsa-let-7b-5p, hsa-
miR-30c-5p, hsa-miR-20a-5p, hsa-miR-122-5p, hsa-miR-
223-3p, hsa-miR-126-3p, hsa-miR-18a-5p, hsa-miR-221-
5p, hsa-miR-885-5p, hsa-miR-30e-3p. These changes of 
circulating miRNA profile had a concordant character in 
the two groups, while they were not observed in samples 
collected right after treatment with the placebo drug. 
Thus, in patients with metastatic breast cancer BP-C1 
therapy induced specific changes in profile of circulating 
miRNAs. These changes might reflect efficacy/toxicity 
of the applied therapy and have a predictive value, which 
need to be further assessed. 
Elena I. Fedoros (Nobel Ltd.; N.N. Petrov National 
Medical Research Center of Oncology, Saint-Petersburg) 
delivered a talk on results of simulation of biological 
activity of the novel polyphenolic ligand of BP-C family 
drugs (in vitro and in silico) addressing a complex problem 
of identification of biological targets for natural polymers. 
A combination of established experimental methods was 
proposed as a possible solution to this problem.
Biological activity of BP-Cx-1 - platform for the 
BP-C family drugs, was assessed by Dr. R. N. Karapetian 
and his group (ChemRar Institute, Moscow), using in 
vitro Cerep Diversity Profile (P9) screening panel. It was 
demonstrated that BP-Cx-1 interacts with 40 of the 97 
tested targets. 
Biological activity of BP-Cx-1 was also simulated 
in silico, using the following input parameters: results of 
HPLC/HPLC-MS, obtained by the scientific group headed 
by Dr. E. I. Savelyeva (Scientific-Research Institute of 
Human Hygiene, Professional pathologies and Ecology 
of Federal Medical-Biological Agency of Russia, Saint-
Petersburg), results of CHN, 13C NMR and FTICR-MS, 
latter ones generated by the group of Prof. I. V. Perminova 
(M.V. Lomonosov Moscow State University, Moscow) 
and results of 1H NMR, generated by Dr. K. A. Krasnov 
(Institute of Toxicology, Saint-Petersburg). CHN analyses 
demonstrated that BP-Cx-1 does not comprise any 
nitrogen-containing components; NMR spectra indicate 
that BP-Cx-1 comprises predominantly highly substituted 
polyphenols. These findings were used as the basis for in 
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To perform in silico biological activity screening 
in ChemBL chemical database, only components with 
molecular masses confirmed by both HPLC-MS and 
FTICR-MS methods, were selected. Matching biological 
activity of BP-Cx-1 identified in the in vitro and in the 
in silico test systems comprises 9 targets: Glucocorticoid 
receptor (NR3C1), Prostanoid EP2 receptor (PTGER2), 
Beta-2 adrenergic receptor (ADRB2), Vasopressin 
receptors (AVPR2, AVPR1A), Thyroid-stimulating 
hormone receptor (TRHR), Adenosine A1 Receptor 
(ADORA1), GABA trans-porter (SLC6A1). 
These identified interactions suggest that BP-Cx-1 
has its own pharmacological activity, first of all, effect on 
inflammations and stress.
Irina V. Perminova (M.V. Lomonosov Moscow 
State University, Department of Chemistry, Moscow) in 
her report entitled Distribution of BP-Cx-1 polyphenolic 
ligand tagged with [3H] in cells and tissues presented 
radiolabeling technique developed by Dr. G.A. Badun for 
preparing tritium-labelled polyphenolic BP-Cx-1 ligand 
and the data from cell distribution and pharmacokinetics 
studies conducted using radiolabeled BP-Cx-1. 
Advantages of using tritium label for pharmacokinetics 
studies include incorporation of its isotope – hydrogen 
– into BP-Cx-1 structure, long half-life - 12.323 ± 0.004 
years, low energy of decay with a release of beta particle 
(Emean= 5.69 keV), and small length of beta-particle path in 
water (~ 1 μm). The labeling was performed using tritium 
thermal activation technique, which provides for non-
selective H/T exchange in polyphenolic ligand. BP-Cx-1 
samples were dissolved at concentration of 5 mg/mL in 
0.15 M NaCl and buffered with 10 mM Na2HPO4 to pH 
7.0. The specific activities of BP-Cx-1 ligand were 8 Ci/g. 
Two cell lines were used for the studies - MCF7/R cells 
- human breast adenocarcinoma cells and NIH3T3 cells - 
normal mouse fibroblasts.
The studies on intracellular localization were 
conducted by Dr. N.S. Melik-Nubarov and his group using 
microautoradiography. The darkening of nuclear emulsion, 
which is indicative of label accumulation, was observed at 
the cell membrane and, which is of particular interest, in 
the nuclear and perinuclear regions of the cells. The higher 
number of “dark spots” covering cell nuclei was observed 
for tumor cells as compared to normal fibroblasts. The 
polyphenolic ligand (BP-Cx-1) showed high affinity for 
binding to the cell surface exceeding that of poloxamers. 
Specific feature of the tested samples is their ability to 
accumulate in the perinuclear region of both tumor and 
normal cells and in the nucleus. Much more pronounced 
nucleotropic effect was observed for the tumor cells as 
compared to the normal cells. 
The labelled ligand (3H-BP-Cx-1) was also used 
for the pilot pharmacokinetic studies. In this experiment, 
BP-Cx-1 was administered at 80 mg/kg; 6 BALB/c mice 
were used: 3 mice were decapitated 5 min after and 3 
mice – 30 min after intravenous injection of 3H-BP-
Cx-1. Liquid Scintillation Counting was used to evaluate 
accumulation of [3H] label in organs of the experimental 
animals. It was shown that upon intravenous injection, the 
highest concentration was observed in lungs (1053 µg/g 
of organ weight at 5 min. and 1239 µg/g of organ at 30 
min.). One order of magnitude lower concentration was 
detected in blood, heart, liver and kidneys. Two orders 
of magnitude lower concentration was detected in brain, 
muscles, pancreas, stomach and spleen. The same effect 
was observed when a sample of humic acid produced from 
coal was tested. Alternative experimental design and a 
different route of administration of the radiolabeled ligand 
(intramuscular instead of intravenous) need to be identified 
to improve understanding of the obtained results. The 
studies were conducted by Dr. G.A. Badun jointly with Dr. 
A.V. Panchenko (N.N. Petrov National Medical Research 
Center of Oncology, St. Petersburg) and Dr. Yu.V. Zhernov 
(Immunology Institute, Moscow).
Evgeny Yu. Drobyshev (N.N. Petrov National 
Medical Research Center of Oncology; Institute of 
Toxicology, Federal Medical-Biological Agency, Saint-
Petersburg) in his presentation “Distribution of metals 
in animals after BP-C1 and BP-C2 treatment” described 
pharmacokinetics, toxicity and tissue distribution of the 
novel platinum-containing (BP-C1) and molybdenum-
containing (BP-C2) products. Role of the polyphenolic 
ligands in transport and elimination of metals are actively 
discussed. Compared to the classic platinum antitumor 
agent – cisplatin, BP-C1, which also contains platinum, 
shows better platinum release kinetics and lower protein 
binding, which result in a lower nonspecific toxicity of 
this product. Besides, smaller concentration of platinum 
was detected in non-target tissues of animals treated with 
BP-C1. In case of BP-C2, which is a radiomitigative 
agent, effect of the polyphenolic ligand on molybdenum 
distribution pattern in tissues was detected. Abnormal 
accumulation of molybdenum in ovaries and unchanged 
tissue-to-blood ratio indicate that the mechanism of 
transport of this metal to ovaries is different from 
that to other tissues. At the same time, molybdenum 
concentration in the brain increased only 2 times, whereas 
based on our other molybdenum speciation studies, 
which demonstrated similar concentration of this element 
in serum and cerebrospinal fluid, we expected it to be 
the same. Based on this we conclude that molybdenum 
transport through blood-brain barrier is not unspecific. BP-
Cx-1 significantly accelerated distribution and elimination 
speed of molybdenum administered with BP-C2. 
Vladimir N. Bykov (S.M. Kirov Military 
Medical Academy, Saint-Petersburg) presented data on 
radioprotective and radiomitigative potential of novel 
polyphenolic compound. Drugs used for protection of 
human beings from ionizing radiation fall under several 
distinct groups. Radioprotectors (“chemical protection”) 
have short-term efficacy and act on physical-chemical 
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and biochemical levels during absorption of the 
ionizing radiation energy. Radiomitigators – are agents 
with long-term efficacy, which promote accelerated 
recovery of radiosensitive tissues exposed to radiation. 
Radiomodulators (“biological protection”) – increase 
resistance of the body to radiation through modulation 
of biological processes and enhancement of antioxidant 
protective mechanisms.
Results of evaluation of radioprotective and 
radiomitigative potential of BP-C2 were presented. To 
evaluate efficacy of BP-C2 in Acute Radiation Syndrome 
(ARS) model with extended monitoring of hematology 
and hematopoietic system, small laboratory animals 
(CBA male mice and Wistar male rats) were subjected to 
ionizing gamma radiation in the doses from 4.0 to 8.0 Gy 
without bone marrow shielding. BP-C2 was administered 
by gavage daily once every second day (in total 10 times) 
at 3 dose levels: 6.0 to 156.2 mg/kg in mice and 3.0 to 93.7 
mg/kg in rats. Total body irradiation was performed once 
after the 5th administration of the drug. After irradiation 
animals were monitored for 30 days. 
BP-C2 increased survival of both mice and rats. 
The most pronounced radioprotective effect in mice was 
observed at dose of 81.0 mg/kg and in rats at dose 93.7 
mg/kg. BP-C2 was most effective at radiation doses from 
5.0 to 6.0 Gy.
In the control group, MLD (Median Lethal Dose) 
was estimated as 5.7 Gy in mice and 5.0 Gy in rats, 
while it reached 6.1 Gy both in mice and rats treated with 
optimal radioprotective doses of BP-C2. Dose Modifying 
Factor (DMF) of the drug constituted 1.1 in mice and 1.2 
in rats.
It was found that BP-C2 at best protects from or at 
least improves the course of such clinical manifestations 
of the ARS as loss of weight, reduced consumption of food 
and water, signs of hypodynamia, including adynamia, 
dyspeptic symptoms and diarrhea, hemorrhagic syndrome, 
manifesting as sanguineous serous discharge from the eyes 
and nose.
The optimal dose of BP-C2 (81.0 mg/kg 10 times) 
increased weight of the spleen (56±4.0 vs. 27±2.0 in 
control group) and Colony-Forming Units count in the 
spleen (8.6±1.10 vs. 5.4±1.10 in Control group) in mice 
irradiated with 5.7 Gy. 
In rats (5.0 Gy, 93.7 mg/kg of BP-C2 10 times), 
the myelokaryocyte count in the bone marrow was 
approximately 1.3 times higher that of the control 
group on day 3 post-exposure, and two-fold increase 
in the myelokaryocyte count was observed by day 14. 
Additionally, recovery of bone marrow hematopoiesis was 
shorter in the BP-C2 group compared to the control group.
Repeated administration of BP-C2 ensured dose 
dependent radioprotection against radiation in the median 
lethal dose range. The use of the drug seems to increase 
the likelihood of favorable resolution of ARS syndrome. 
BP-C2 accelerated bone marrow hematopoiesis recovery 
and exerted favorable effect on hematopoietic system.
Andrey V. Panchenko (N.N. Petrov National Medical 
Research Center of Oncology, Saint-Petersburg) in his 
report “Possibilities of using new polymeric polyphenol 
complex BP-C3 for the adjunct treatment of patients 
receiving chemotherapy” presented original data on the 
effects of BP-C3 on toxicity induced with 5-fluorouracyl 
in SHR mice and on efficacy of chemotherapy applied to 
mammary carcinoma bearing FVB/N mice transgenic with 
HER-2/neu. 
Antitumor therapy using 5-fluorouracil (5-FU) and 
other cytostatic agents is often associated with various 
side effects, thus development of an adjunct treatment for 
amelioration of toxicity of chemotherapy in cancer is an 
important aim. 
BP-C3 (80 mg/kg b.w. by gavage for 18 days) 
significantly reduced hematological and intestinal 
disorders associated with 5-FU (150 mg/kg b.w. single 
intraperitoneal injection). BP-C3, when administered on 
either preventative/therapeutic or therapeutic schedule, 
demonstrated different effects on hematological 
parameters of hematopoietic organs and peripheral blood. 
Administration of ВР-C3 24 hours after 5-FU ameliorated 
both leukopenia/myelosuppression and prevented anemia 
in the mice, while when BP-C3 was stared 7 days prior 
to 5-FU only improvement of white blood counts was 
achieved. Both administration schedules significantly 
improved intestinal crypt survival after 5-FU induced 
damage. 
In another experimental setting, addition of BP-
C3 to CAF-regimen, Gemcitabine or Gemcitabine with 
Cisplatin administered to animals with mammary tumors, 
was assessed. BP-C3 did not reduce efficacy of these 
regimens. Most efficient, in terms of antitumor activity, 
was CAF regimen, stabilizing tumor development in about 
60% of experimental animals (p=0.0006 vs Control) and 
providing up to 64% reduction of tumor volume. 
Thus BP-C3 has a potential as a supportive care 
product for cancer patients, where it could be used to 
ameliorate chemotherapy related toxicities without 
affecting tumor sensitivity.
Vladimir N. Anisimov (N.N. Petrov National 
Medical Research Center of Oncology, Saint-
Petersburg) presented data from a study on evaluation 
of geroprotective and anti-carcinogenic effects of 
polyphenolic composition BP-C3 in female SHR mice. 
BP-C3 is a geroprotective composition developed on the 
basis of BP-Cx-1 polyphenolic ligand.
In this study, age-indicating parameters of 60 
mice lifetime exposed to 0.005% solution of BP-C3 
administered with drinking water (10 mg/kg daily) was 
compared to 60 mice of the control group.
Age-related dynamics of the body weight, food and 
water consumption were not affected by BP-C3 exposure 
in SHR mice. Treatment with BP-C3 decreased rectal 
temperature by 0.2-0.4 °C and postponed age-related 
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switching-off of estrous function in the experimental 
animals. BP-C3 increased mean life span by 8.4% up to 
646±18.7 days (p<0.05), mean life span of the last 10% 
surviving animals by 12.4% (to 863±3.7 days (p<0.01)) 
and life span of tumor-free mice by 11.6% (to 676±24.3 
days (p<0.05)). A tendency in ability of BP-C3 to inhibit 
development of spontaneous tumors in SHR mice was 
detected (p=0.166, log rank test: age at detection of the 
first tumor increased by 16% and total number of detected 
tumors decreased 1.6 times. Tumors developed in both 
groups were predominantly mammary adenocarcinomas. 
Frequency of non-tumor pathologies did not differ 
statistically between the groups. 
When compared with other known geroprotective 
compounds, such as metformin, rapamycin and melatonin 
with effects on energy homeostasis, reproductive 
homeostasis and adaptation (stress resistance, immune 
activity etc.), low toxicity of BP-C3, its effect on delay 
of aging of estrous function and on increased survival 
with delayed in tumor development strongly indicate 
geroprotective activity of this composition.
Tea Kirkegaard Nielsen (Meabco AS; University of 
Copenhagen, Copenhagen) in her report «Results from 
analyses of the immunoregulatory properties of BP-C 
family drugs» presented a proposition for the common 
action of the members of the BP-C family.
BP-C3 prolongs the lifespan of mice, BP-C1 shrinks 
tumors, and BP-C2 mitigates damages from radiation and 
improves tissue healing. The link between these activities 
is the immune system which plays a pivotal role for all 
phenomenons. The incidence of lifestyle diseases such as 
cancer, liver cirrhosis, obesity, diabetes, among others, are 
all concurrent with, or caused by, immune malfunctioning. 
The tissue surrounding or infiltrating a tumor (tumor 
microenvironment) is decisive for the growth rate and 
for the proliferation rate of the cancer cells. The tissue 
contains a myriad of inflammatory signals which are 
involved in activation of the immune system to attack 
the cancerous cells. However, if these cells also express 
immune suppressor signals, shielding them from attack, 
the inflammatory signals are much less harmful and can 
instead provide growth factors stimulating tumor growth. 
Age-related susceptibility to opportunistic 
pathogens and lack of response to vaccines, are also 
linked to immune dysfunction, a phenomenon referred 
to as immunosenescence. Increased inflammatory milieu 
and unfavorable composition of immune elements 
are highlighted as the cause of immunosenescence. 
Obesity, alcohol consumption, exposure to pollution, and 
smoking, are all directly linked to increase in local or 
systemic inflammation. Skin damage is followed by local 
inflammation (damaged tissue and pathogen depletion) 
and secondarily, cell proliferation (tissue regeneration). 
The BP-C family is a mixture of complex 
compounds constituting several aromatic carbohydrates 
rich in antioxidant moieties. Based on structure and 
medical characteristics we hypothesized that BP-C 
holds anti-inflammatory properties. To investigate this, 
we isolated CD14-positive cells (primarily monocytes) 
from healthy donors and exposed them in vitro to innate 
immune triggering factors (e.g. lipopolysaccharide, 
LPS) to stimulate inflammation. We observed that the 
inflammatory cytokine secretion from the monocytes 
were highly suppressed after incubation with BP-Cx-1. 
The results were intriguing; the inhibition applied not 
only to one cytokine but several, and these were the ones 
known to be most inflammatory (IFN-γ, TNF-α, IL-1b). 
We conclude that the BP-C family might cease excess of 
inflammatory elements and this tendency will be further 
investigated in vivo.
Conference was summarized by Alexander M. 
Scherbakov (N.N. Petrov National Medical Research 
Center of Oncology, St. Petersburg) who expressed sincere 
admiration of quality of the research results, presented 
by the speakers, emphasized strong potential that lies 
in development of new polyphenolic drugs for cancer 
patients, drugs that could nicely fit the trends observed in 
the modern oncology – extension of quality life of cancer 
patients.
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